Literature DB >> 10791856

The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients.

O Kawashima1, M Kamiyoshihara, S Sakata, K Endo, R Saito, Y Morishita.   

Abstract

BACKGROUND: Serum-soluble interleukin-2 receptor (IL-2R) concentrations have been found to be elevated in cancer patients. However, the importance of this finding in patients with non-small-cell lung cancer (NSCLC) has not been previously established.
METHODS: Preoperative serum-soluble IL-2R concentrations were determined in 65 consecutive patients with operable NSCLC. The correlation of preoperative serum-soluble IL-2R concentrations with various clinicopathological features of this cancer was evaluated to clarify the clinical significance of this parameter.
RESULTS: Although serum-soluble IL-2R concentrations were not significantly higher in operable NSCLC patients than in normal controls (P = .1180), serum-soluble IL-2R concentrations were significantly higher in patients with stage IIIB or IV disease than in normal controls (P = .0001). The presence of intrapulmonary metastasis was the only clinicopathological feature that was significantly correlated to serum-soluble IL-2R concentration (P = .0004). The sensitivity of serum-soluble IL-2R concentration in identifying the presence of intrapulmonary metastasis was 87.5%; specificity was 75%.
CONCLUSIONS: Elevated preoperative serum-soluble IL-2R concentrations in patients with operable NSCLC reflect the occurrence of intrapulmonary metastasis. Preoperative examination of serum-soluble IL-2R concentrations may be valuable in the detection of the intrapulmonary metastasis preoperatively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10791856     DOI: 10.1007/bf02523660

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.

Authors:  Shigenori Kanazawa; Kazuyuki Yamaguchi; Yoshimi Kinoshita; Yutaka Komiyama; Mikiko Muramatsu; Shosaku Nomura
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

2.  The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.

Authors:  Ewa Bien; Malgorzata Rapala; Malgorzata Krawczyk; Anna Balcerska
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

Review 3.  Sarcoma treatment in the era of molecular medicine.

Authors:  Thomas Gp Grünewald; Marta Alonso; Sofia Avnet; Ana Banito; Stefan Burdach; Florencia Cidre-Aranaz; Gemma Di Pompo; Martin Distel; Heathcliff Dorado-Garcia; Javier Garcia-Castro; Laura González-González; Agamemnon E Grigoriadis; Merve Kasan; Christian Koelsche; Manuela Krumbholz; Fernando Lecanda; Silvia Lemma; Dario L Longo; Claudia Madrigal-Esquivel; Álvaro Morales-Molina; Julian Musa; Shunya Ohmura; Benjamin Ory; Miguel Pereira-Silva; Francesca Perut; Rene Rodriguez; Carolin Seeling; Nada Al Shaaili; Shabnam Shaabani; Kristina Shiavone; Snehadri Sinha; Eleni M Tomazou; Marcel Trautmann; Maria Vela; Yvonne Mh Versleijen-Jonkers; Julia Visgauss; Marta Zalacain; Sebastian J Schober; Andrej Lissat; William R English; Nicola Baldini; Dominique Heymann
Journal:  EMBO Mol Med       Date:  2020-10-13       Impact factor: 12.137

4.  Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy.

Authors:  Yung-Che Chen; Chang-Chun Hsiao; Kuang-Den Chen; Yu-Chiang Hung; Ching-Yuan Wu; Chien-Hao Lie; Shih-Feng Liu; Ming-Tse Sung; Chung-Jen Chen; Ting-Ya Wang; Jen-Chieh Chang; Petrus Tang; Wen-Feng Fang; Yi-Hsi Wang; Yu-Hsiu Chung; Tung-Ying Chao; Sum-Yee Leung; Mao-Chang Su; Chin-Chou Wang; Meng-Chih Lin
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

Review 5.  On the role of sIL-2R measurements in rheumatoid arthritis and cancers.

Authors:  Anna Maria Witkowska
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

6.  Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma.

Authors:  Akinori Masuda; Kyoko Arai; Daisaku Nishihara; Tomoya Mizuno; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Hideyuki Abe; Masahiro Yashi; Yoshitatsu Fukabori; Ken-Ichiro Yoshida; Takao Kamai
Journal:  Biomed Res Int       Date:  2014-06-25       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.